Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1826 + BP-102
- Development stage
- Unknown
- Lead developer
- Suzhou Suncadia Biopharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-1826 + BP-102 is a combination of two investigational monoclonal antibody-based therapies under clinical development for oncology. **SHR-1826** is an antibody-drug conjugate targeting c-Met (hepatocyte growth factor receptor), intended to deliver a cytotoxic payload specifically to c-Met–expressing tumors, thereby inhibiting tumor cell proliferation and survival[1][3][5]. **BP-102** is a humanized recombinant monoclonal IgG1 antibody, although its precise target (other than being used in combinations with immunotherapy) is not well characterized in published data. Clinical trials have evaluated this combination (or related combinations) in advanced or metastatic solid tumors, including colorectal cancer. The mechanism of SHR-1826 is primarily c-Met inhibition via targeted delivery of a cytotoxic agent, while BP-102 is likely involved as an immunomodulatory or anti-tumor monoclonal antibody, though its detailed MOA is not specified in the public domain[9].
- Other names
- SHR-1826 + BP-102
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on SHR-1826 + BP-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1826 + BP-102.